Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2021

View Archived Issues

First patient dosed in phase II study of ZN-c3 in uterine serous carcinoma

Vaxart's IND application for S-only oral tablet COVID-19 vaccine cleared in U.S.

Hovione Scientia describes ligand drug conjugates including BET inhibitors

Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors

New CDK and TRK inhibitors identified at Hangzhou Innogate Pharma

Ascentage Pharma discovers mutant GTPase KRAS inhibitors

FDA clears IND for phase I/II MARINA study of AOC-1001

Dosing begins in phase I study of mRNA-6231

Prometheus initiates phase IIa APOLLO-CD study of PRA-023 in Crohn's disease

Discovery of SR-42667: a tau-SH3 interaction inhibitor that prevents Abeta toxicity

Phase II data show safety and efficacy of OCS-02 in dry eye disease

Gem gene sparkles as ischemic stroke drug discovery target

China's NMPA approves INDs for IASO's CD19/CD22 CAR-T therapy

Collagenase clostridium histolyticum improves foot function in plantar fibromatosis study

Abcentra studies orticumab in subjects with psoriasis and cardiometabolic risk factors

Intranasal vaccination with ChAdOx1 nCoV-19 reduces viral shedding in preclinical models

ST-067 enters first-in-human study in relapsed or refractory solid tumors

Phase I trial evaluates iPSC-derived CAR T-cell therapy FT-819 for CD19+ malignancies

Phase I data with ANG-3070 pave way for phase II study in primary proteinuric kidney diseases

CTA approved in Vietnam for phase I/II/III study of SARS-CoV-2 vaccine ARCT-154

Dosing underway in phase I/II study of KRAS G12C inhibitor JAB-21822

Annovis reports interim phase II data on Posiphen in Alzheimer's and Parkinson's disease

ACD-856 shows preclinical effects on cognition, enters phase I study

FDA authorizes IND for phase I testing of Sorrento's CD38 DAR-T cell therapy candidate

Luye Pharma files IND in U.S. to study next-generation VMAT2 inhibitor LY-03015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...